Clinical Intelligence/Clinical Efficiency

BioIntelliSense announces partnership with TRISH

BioIntelliSense

In partnership with the Translational Research Institute for Space Health (TRISH), the BioButton® medical-grade wearable device will monitor physiologic biometrics during the upcoming Polaris Dawn mission

BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company, today announced its partnership with the Translational Research Institute for Space Health (TRISH) to further understanding of human health in space. The BioButton® medical grade wearable device will be used for commercial spaceflight research programs and notably during the upcoming five-day Polaris Dawn mission. This historic mission will be flown by SpaceX and is scheduled to launch after March 2023. Medical and scientific research on human health in space promotes the advancement of translational technologies by adapting known technology for space applications, and by using space-based insights to improve healthcare at home.

“BioIntelliSense has proudly gained industry recognition for its innovative and comprehensive portfolio of continuous multi-parameter monitoring solutions for application in the acute care environment, at home settings and now, in the next frontier of space,” said James Mault, MD, founder and CEO of BioIntelliSense. “As a lifelong space exploration enthusiast, it is a tremendous honor to be working with TRISH on health research that can benefit astronauts and crews during commercial space flight and for the BioButton devices to be part of the upcoming Polaris Dawn mission.”

The BioButton multi-parameter device is designed to be worn on the upper left chest and will passively capture trending physiologic and movement data from the Polaris Dawn crew during its milestone mission. The future of healthcare is here. Today, the BioIntelliSense Data-as-a-Service (DaaS) platform and clinical intelligence solution is commercially available and rapidly adopted by acute and post-acute providers in the U.S. along with select international markets.

“TRISH is proud to partner with innovative healthcare technology leaders like BioIntelliSense as we further our understanding of human health in space,” said James Hury, TRISH Chief Innovation Officer and Deputy Director. “Our EXPAND (Enhancing eXploration and ANalog Definition) commercial spaceflight health research platform provides unique opportunities to rapidly test technologies in orbit, as well as collect new datapoints on the health impact of spaceflight for a wider, more diverse population.”

BioIntelliSense (Booth #5025) and TRISH (Space Health Pavilion #2636) will be showcasing the BioButton wearable device and clinical intelligence solution at the premier HLTH 2022 conference November 13 – 16 in Las Vegas, NV.

For the latest news and information on how BioIntelliSense is making early detection simple™ through medical-grade wearable technology and cost-effective data services, visit our website at biointellisense.com and follow BioIntelliSense on Twitter and LinkedIn.

Related posts

Zora Biosciences Licenses Ceramide Technology to Quest Diagnostics

PR Newswire

Ciitizen and RARE-X Collaborate to Improve Clinical Efficiency

Business Wire

Brooks Participates in KeyBanc Life Sciences & MedTech Forum

PR Newswire